Classes
- Clinical 10 days - Department of Oncology +1D0110ONK | Second Faculty of Medicine
- Clinical Radiotherapy +1D0503007 | Second Faculty of Medicine
- Radiotherapy +1D0505002 | Second Faculty of Medicine
- Clinical Radiotherapy - Training +1D0505009 | Second Faculty of Medicine
- OS - Selected chapters from oncologyDVA1099 | Second Faculty of Medicine
Publications
- Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry2017 | First Faculty of Medicine
- Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy2016 | Publication without faculty affiliation
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)2016 | Publication without faculty affiliation
- Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry2015 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy2015 | Publication without faculty affiliation
- Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry2014 | Faculty of Physical Education and Sport, First Faculty of Medicine, Second Faculty of Medicine
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial2014 | Second Faculty of Medicine
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen2012 | Second Faculty of Medicine
- EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer2008 | Second Faculty of Medicine
- Prevention, diagnosis and treatment of cancer-associated thromboembolism2023 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...